Navtemadlin

4 trials 1 recruiting

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

3 Completed trials

1 Sponsors

21 Countries

Phase III

Phase II/III

Phase I/II

Phase III: 1 Phase II/III: 2 Phase I/II: 1

Indications tested

Primary myelofibrosis 2 Myelofibrosis 1

Sponsors using this IMP

Kartos Therapeutics Inc. 4

All trials

4 total

Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting

2023-504724-25-00 Phase III 13 countries Kartos Therapeutics Inc.
Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera M… Ended

2024-514468-26-00 Phase I/II 2 countries Kartos Therapeutics Inc.
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treat… Ended

2024-513912-89-00 Phase II/III 13 countries Kartos Therapeutics Inc.
Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended

2022-502196-31-00 Phase II/III 15 countries Kartos Therapeutics Inc.

Showing 1–4 of 4 trials

← All drugs A–Z